Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Doxofylline→

Doxofylline Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
69975-86-6
Molecular formula
C11H14N4O4
Molecular weight
266.25 g/mol
Drug class
Methylxanthine bronchodilatorxanthine derivative
Mechanism of action
The exact molecular mechanism is not fully resolved. Doxofylline produces bronchodilation and has been described as modulating phosphodiesterase/cyclic-AMP signalling; unlike theophylline, it has markedly reduced affinity for adenosine receptors and does not show the same adenosine-antagonist profile.
Indications / reported uses
  • Bronchial asthma
  • Chronic obstructive pulmonary disease (COPD) and other obstructive airway conditions where doxofylline is authorised; indication and formulation differ by jurisdiction

Sources: MIMS India — Doxofylline information · PubChem — Doxofylline and ChEBI summary · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Doxofylline Environmental Risk Assessment (ERA) (the Doxofylline ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.